New studies show ABT-494 is an effective alternative to anti-TNF alpha agents, as well as methotrexate, for RA. Also, the FDA issued a warning against using tramadol for young patients due to their increased risk of respiratory side effects…
Celiac Disease in Pediatric Patients
A retrospective study shows that some patients presenting for pediatric rheumatology evaluation test positive for celiac disease—some without showing any gastrointestinal manifestations. Treatment includes a gluten-free diet…
Researchers Identify Molecule That Promotes Osteogenesis
New insights into bone cell biology—including the identification of parbendazole, a bone anabolic compound that promotes bone formation—may lead to better treatments for osteoporosis…
Legalities of Telemedicine
A brief has been filed with the U.S. Supreme Court that, if the court decides to hear the case, could have wide-ranging implications for online medical care and the limits of a physician’s First Amendment right to free speech. Medical Advice Via e-Mail Institute for Justice Senior Attorney Jeff Rowes filed the brief at the…
Musculoskeletal Ultrasound: A Valuable Tool for Diagnosing Rheumatic Illnesses
Musculoskeletal (MSK) ultrasound is a valuable imaging modality for the practicing rheumatologist and provides an efficient tool with high diagnostic value in the evaluation of patients with musculoskeletal complaints. The use of MSK ultrasound has evolved in the U.S. due to the emergence of less-expensive, portable ultrasound units, which provide high-quality gray-scale and power Doppler…
Adalimumab, Tacrolimus Effective for Treating Refractory Ulcerative Colitis
NEW YORK (Reuters Health)—The human IgG1 anti-TNF antibody adalimumab is safe and effective for short- and long-term treatment, and the calcineurin inhibitor tacrolimus given short-term brings remission, in patients with refractory ulcerative colitis, according to two new studies in the Journal of Crohn’s and Colitis. In the first study, online Sept. 21, Dr. Tamas Molnar…
FDA Declines to Expand Approval of Pfizer Arthritis Drug Xeljanz
(Reuters)—U.S. health regulators declined to approve Pfizer Inc’s oral rheumatoid arthritis drug Xeljanz (tofacitinib) to treat moderate to severe cases of plaque psoriasis, the drugmaker said on Wednesday. Pfizer said it received a complete response letter from the Food and Drug Administration. Such letters typically outline concerns and conditions that must be addressed in order…
Rheumatologist Robert H. Shmerling, MD, Volunteers Time for Children Affected by Domestic Violence
On any Thursday from 7 p.m. to 8 p.m., you can find Robert H. Shmerling, MD, playing tag, basketball or even roughhousing with a group of children at Second Step, a transitional living program that offers victims of domestic violence in the Boston area a safe place to live and opportunities to go back to…
Opinion: Insurance Companies Use Medically and Fiscally Irresponsible Formularies
Receipt of an unsolicited communication that a sweepstakes award has been won may con some people (especially, but not limited to, those underprivileged or undereducated as to legalities), but can’t fool all of the people all of the time. The names of the organizations and products involved are often marketing tool inventions, which imply special…
Arthritis Power App Can Help Patients Monitor Symptoms, Improve Office Visits
For the past 16 years, the website, creakyjoints.org, founded by arthritis patient Seth Ginsberg and social entrepreneur Louis Tharp, has offered arthritis patients and their families a safe online community where they can receive meaningful support and education. In March, the online portal added a new initiative—Arthritis Power, the first-ever patient-led, patient-generated, app-based research registry…
- « Previous Page
- 1
- …
- 549
- 550
- 551
- 552
- 553
- …
- 816
- Next Page »